Overall, the current pioneering preclinical findings reveal the potential of LY-induced S6K1 blockage as an efficacious therapeutic treatment to hamper fat mass expansion and relieve the burden of dyslipidemia and fatty liver in obese patients. The gene discussed is RPS6KB1; the disease is metabolic syndrome.